Skip Navigation



Annals of Oncology Advance Access published online on September 15, 2006
Annals of Oncology, doi:10.1093/annonc/mdl282
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/11/1709    most recent
mdl282v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gore, L.
Right arrow Articles by Eckhardt, S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gore, L.
Right arrow Articles by Eckhardt, S. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received May 17, 2006
Revised July 3, 2006
Accepted July 4, 2006

original article

A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors

L. Gore 1 *, S. N. Holden 1, R. B. Cohen 2, M. Morrow 1, A. S. Pierson 1, C. L. O'Bryant 1, M. Persky 1, D. Gustafson 1, C. Mikule 1, S. Zhang 3, P. A. Palmer 4, and S. G. Eckhardt 1

1 Department of Pediatrics, Medical Oncology, and Pharmacology, University of Colorado Cancer Center, Aurora, CO
2 Department of Medical Oncology, University of Virginia, Charlottesville, VA
3 Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
4 Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, USA; Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium

* To whom correspondence should be addressed.
L. Gore, E-mail: lia.gore{at}UCHSC.edu


  Abstract

Background: To evaluate the toxicity and pharmacological and biological properties of the farnesyl protein transferase (FPTase) inhibitor, tipifarnib (R115777, ZARNESTRATM) and capecitabine administered for 14 days every 3 weeks.

Patients and methods: Patients with advanced cancers received twice daily tipifarnib (100-500 mg) and capecitabine (1000-1125 mg/m2) for 14 days every 3 weeks. Pharmacokinetics of tipifarnib, capecitabine and 5-fluorouracil (5-FU) were determined. Peripheral blood mononuclear cells were analyzed for farnesylation of the HDJ2 chaperone protein and FPTase activity.

Results: Forty-one patients received 185 courses of treatment. Diarrhea and palmar-plantar erythrodysesthesia were dose limiting at 300 mg tipifarnib/1125 mg/m2 capecitabine b.i.d. When the capecitabine dose was fixed at 1000 mg/m2 b.i.d., neutropenia was dose limiting at 400 and 500 mg b.i.d. of tipifarnib. Capecitabine did not affect the pharmacology of tipifarnib at 100-300 mg b.i.d., although tipifarnib significantly increased the C max of 5-FU at 400 mg b.i.d. HDJ2 farnesylation and FPTase activity decreased between 200 and 400 mg b.i.d. doses of tipifarnib, without a dose-response relationship. Five patients demonstrated partial remissions and 11 patients maintained prolonged stable disease.

Conclusions: Tipifarnib and capecitabine are well tolerated at 300 mg/1000 mg/m2 b.i.d., respectively, resulting in biologically relevant plasma concentrations and antitumor activity. The recommended dose for further disease-focused studies is 300 mg b.i.d. tipifarnib and 1000 mg/m2 b.i.d. capecitabine, given for 14 days every 3 weeks.

Keywords: capecitabine; farnesyltransferase inhibitor; pharmacokinetics; phase I; tipifarnib.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Findlay, G. von Minckwitz, and A. Wardley
Effective oral chemotherapy for breast cancer: pillars of strength
Ann. Onc., February 1, 2008; 19(2): 212 - 222.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L.-A. Martin, J. E. Head, S. Pancholi, J. Salter, E. Quinn, S. Detre, S. Kaye, A. Howes, M. Dowsett, and S. R.D. Johnston
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo
Mol. Cancer Ther., September 1, 2007; 6(9): 2458 - 2467.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.